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Abstract 
Objective –The aim of this study was to analyse the changes in new certifications for both sight 
impairment (SI), and severe sight impairment (SSI, blindness) in Wales due to diabetic 
retinopathy/maculopathy (DR) between 2007 and 2015. 
Research Design and Methods – This is a retrospective analysis of annual data of new certifications 
for visual impairment and blindness (CVI) for England and Wales derived from the national database 
provided by the Certifications Office, Moorfields Eye Hospital, over a period of 8 years from 2007.  
Results – In Wales there were 339 less new certifications for both SI and severe SSI  from any cause 
combined from 2007-2008 to 2014-2015. The number SI and SSI combined specifically due to DR was 
reduced by 22 in people with known diabetes.  This was a reduction of new certifications, over the 
observation period of 82.4 to 46.9 per 100,000 (-43.1%) with a fall in SSI from 31.3 to 15.8 per 
100,000 (-49.4%), respectively. During this observation period however, there was a parallel increase 
in 52,229 (39.8%) persons with diabetes in Wales. 
Conclusions – Whilst acknowledging the limitations of the certification process and the increasing 
numbers of persons with diabetes the incidence of SI and SSI per 100,000 population of persons with 
diabetes in Wales has almost halved over an 8-year period up to 2015.  This may reflect the earlier 
diagnosis of DR and sight-threatening DR since the introduction of screening and/or improved 
diabetes management with timely onward referral and newer treatments. 
 
 
Article Summary 
Strengths and Limitations of this study 
 A key limitation of our analysis is a consequence of the non-compulsory and inconsistent 
process of reporting/certification of visual loss (sight impairment and severe sight 
impairment) which currently requires a consultant ophthalmologist to complete a 
certification of vision impairment (CVI or CVI-W) rather than being population based 
compounded by the reluctance of patients to be registered as visually impaired/blind.  
 The strength of our study relates to its nationwide coverage, unified data base, providing 
important epidemiological information on the trends in new certification of visual 
impairment due to diabetic retinopathy as the main cause, in Wales, over an 8-year period.  
 An additional strength of this study is that the time period it covers is when a nationwide 
screening programme was introduced to reduce severe sight impairment (blindness) by the 
early detection and treatment of sight-threatening diabetic retinopathy and secondly raise 
awareness to the presence of DR when enhanced medical management can prevent 
progression. 
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Introduction 
In 2015 an estimated 415 million people worldwide had diabetes mellitus, with DR amongst its 
most feared complications capable of causing visual impairment and blindness (1). Therefore, the 
predicted global increase in diabetes prevalence to 642 million by 2040 is of considerable public 
health concern due to its adverse effect on both the individual concerned and society in general (2-
4). Previously, in 2012 a pooled meta-analysis was carried out including 35 studies worldwide 
involving people with diabetes where DR was determined from retinal photographs estimated that 
34.6% had evidence of any DR and with 10.2% having vision threatening DR (5). The prevalence of 
any DR in the our Welsh population during 2005-2009 was 32.4% with 29% non-sight-threatening DR 
and 3.4% sight-threatening DR (6). The increasing prevalence of diabetes is acknowledged to 
represent a major public health problem worldwide and DR is amongst the most feared 
complication, leading to sight impairment (SI) and severe sight impairment (SSI)if not detected and 
treated at an early stage, and is therefore prioritised on the global public health agenda (7, 8). The 
societal costs of SI due to DR are significant and include severe reduction in quality of life, loss of 
productivity and increased healthcare costs (2, 4, 9).  
 
In its ‘Action plan for the prevention of avoidable blindness and visual impairment; 2009-2012’ the 
World Health Organisation has highlighted the importance of recording SI and SS], in  in an attempt 
to monitor the impact of various strategies to eliminate preventable SI and SSI globally (8).  
Recording the number of people who are SSI  in England and Wales was initiated in 1851, and 
between 1930 and 2003 a designated certificate (BD8) was employed which required the signature 
of an ophthalmologist with the cause of low vision included from 1950 onwards (10-15) . The BD8 
was superseded in 2005 by the certificate of vision impairment (CVI) for England and later in 2007 its 
equivalent for Wales (CVI-W) which are crown copyright under the ownership of the government. A 
copy of the CVIs are sent to the Certification Office, London, for anonymised epidemiological analysis 
and which is funded by the Royal National Institute for the Blind (RNIB) operating under the 
governance of the Royal College of Ophthalmologists. Since 2012, despite their limitation, 
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certification numbers have been used in an attempt to indicate the burden of preventable sight loss 
and which are included in the Public Health Outcomes Framework by the Department of Health, UK 
Government.  Between 1999 to 2000 the major causes of SSI in working aged adults (between 16 
and 64 years) in England and Wales were DR/maculopathy (17.7%), hereditary retinal diseases 
(15.8%) and optic atrophy (10.1%) (16, 17).  However, in a more recent analysis for 2009-2010 the 
order of the three main causes of SSI had changed to hereditary retinal disorders (20.2%), 
DR/maculopathy (14.4%) and optic atrophy (14.1%) (18). DR was therefore, for the first time in five 
decades, no longer the leading cause of certifiable SSI in England and Wales, a most encouraging 
trend from a public health standpoint.   
 
In Wales a screening program for DR was launched in 2003 and by the end of 2006 all persons 
known to have diabetes in Wales, aged 12 years or over, and under the care of general practice 
located within Wales had been offered an appointment for screening.  Therefore, the time period 
covered in this analysis corresponds with the time when screening was provided on a national basis 
implementing standardised quality assured methods to include photography and grading. This 
retrospective analysis was conducted in order to address whether the introduction of Diabetic Eye 
Screening in Wales (DESW) has had any impact on the level of certification for SI and SSI in Wales 
between 2007 and 2015 by virtue of the earlier detection of DR and its subsequent management. 
 
Methods 
Numerator 
The numerator included the causes of new CVI-W of both SI and SSI for Wales were sourced from 
the Certifications Office, at Moorfields Eye Hospital, London. Details of data entry and transmission 
using the BD8 certificate causes of blindness recorded by Ophthalmologists and CVI forms have been 
reported previously (18, 19). All patients provided explicit consent for certification and for 
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anonymised data to be sent to the Certifications Office. The number of new certifications of SI and 
SSI due to diabetic eye disease (retinopathy/maculopathy) included those cases where the main 
cause of certifiable SI or SSI was diabetic retinopathy/maculopathy and those where the main cause 
was recorded as multiple conditions but a contributory cause was diabetic eye disease. To be 
certified as SSI , sight assessed using the Snellen Chart, while wearing any glasses or contact lenses, 
will fall into the following categories:  visual acuity (V/A) of less than 3/60 with a full visual field, or 
V/A between than 3/60 and 6/60 with a severe reduction of field of vision, such as tunnel vision, or 
V/A of 6/60 or above but with a very reduced field of vision, especially if a lot of sight is missing in 
the lower part of the field. A definition of SI requires the sight to fall into one of the following 
categories, while wearing any glasses or contact lenses, a V/A of 3/60 to 6/60 with a full field of 
vision, or V/A of up to 6/24 with a moderate reduction of field of vision or with a central part of 
vision that is cloudy or blurry, or V/A of 6/18 or even better if a large part of the field of vision, a 
whole half of the vision, is missing or a lot of the peripheral vision is missing. Certification for SI or 
SSI is decided upon by a consultant ophthalmologist. Incidence data was provided for SI and SSI for 
each year running from April 2007 to March 2015 derived from the certifications for SI and SSI 
covering a two-year period. 

Denominator  
Annual population estimates for Wales were obtained from the Office of National Statistics and were 
based on the mid-year estimates.  Between 2007 and 2010 the estimates were adjusted to bring 
them into line with the official mid-2011 population estimates published in 2013 (20).  The number 
of persons with diabetes in Wales is recorded annually by the Quality and outcomes Framework 
(QoF) in Primary Care (21). QoF is a voluntary reward and incentive programme which aims to 
standardise improvement in the delivery of primary medical services.  The estimate for the 
population with diabetes for the last period of the certification timescale was used as the 
denominator. 
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Statistical analysis 
The incidence of visual impairment (SI and SSI) due to any cause in Wales were calculated using the 
total number of new certifications and the population estimates for each yearly time period 
between 2007 and 2015. In addition the incidence of SI and SSI related to DR were calculated using 
the QoF estimates of people with known diabetes in Wales.  The results are represented as the 
combined total (SI plus SSI), SI and SSI individually when due to either any cause or DR in the 
population of Wales.  The percentage change in the incidence of new certifications for SI and SSI due 
to any cause or DR during each of the eight annual observation periods were also calculated. 
 
Results 
Between 2007 - 2008 and 2014-2015 in Wales there was an overall reduction in new certifications 
for SI and SSI combined from any cause of 339 i.e. from 1582 to 1243, equivalent to 12.2 per 100,000 
of the population representing a decrease of 21.4% over the 8-year observation period (Table 1). The 
new certifications for SI fell by 24.2% from 26.9 (95% confidence interval [CI] 25.1,28.8)  per 100,000 
population in 2007-2008 to 20.4 (95% CI 18.8, 22.0) per 100,000 in 2014-2015. For both parameters, 
a temporary and unexplainable increase was seen between 2008 and 2009 after which there was a 
reduction year on year for the remainder of the study period.  However, new certifications for SSI 
have fluctuated over the observation period with a peak at 2008-2009 of 25.6 (95%CI 23.8, 27.4) per 
100,000 population followed by a lesser peak during 2011-2012 before reaching a nadir of 18.3 
(95%CI 16.9, 19.9) per 100,000 during the final year compared to 22.5 (95% CI 20.9, 24.3) per 
100,000 during the initial year period of 2007-2008.  
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The number of new certifications for SI and SSI combined in Wales due to DR during 2007-2008 
increased from 108 to a peak of 140 certifications during 2008-2009. Thereafter the numbers fell to 
86 certifications during 2014-2015, a reduction of 20.4% from the initial period of 2007-2008 (Table 
2).  Similarly, there was a temporary increase in both SI and SSI during the second annual period of 
observation with SI certifications thereafter falling consistently from 89 to 51 during 2014-2015 a 
reduction of 42.7% and SSI falling from 51 to 29 certificates being a fall of 43.1% over the remaining 
seven years of the study. The overall reduction in SI and SSI combined, SI and SSI for the entire study 
period from 2007-2008 to 2014-2015 was 22.2%, 23.8% and 35.7% respectively.  For the population 
of Wales the initial rate of new certifications in 2007-2008 for SI and SSI combined, SI and SSI was 3.6 
(95%CI 3.0, 4.3), 2.1 (95%CI 1.7, 2.7) and 1.4 (95%CI 1.0, 1.8) per 100,000 respectively followed by 
slight increase in the second year to 4.6 (95%CI 3.9, 5.4), 2.9 (95%CI 2.4, 3.6) and 1.7 (95%CI 1.3, 2.2) 
per 100,000 respectively and then a general trend downwards to the lowest rate of 2.8 (95%CI 2.2, 
3.4), 1.6 (95%CI 1.3, 2.2) and 0.9 (95%CI 0.7, 1.3) per 100,000 respectively seen during 2014-2015. 
 
Over the eight-year observation period the number of persons known with diabetes in Wales  
increased by 52,000 from 131,119 in 2007-2008 to 183,348 in 2014-2015 (Table 3) representing an 
increase in the prevalence of diabetes in Wales from 4.3% in 2007-2008 to 5.9% in 2014-2015.  
During this time, there was an increase in the rate of new certifications for SI and SSI combined, SI 
and SSI from the first to the second year (2007-2008 to 2008-2009) from 82.4 (95%CI 68.2, 99.4), 
48.8 (95%CI 38.2, 62.3) and 31.3 (95%CI 23.1, 42.4) to 100.7 (95%CI 85.4, 118.8), 64.5 (95%CI 52.0, 
78.8) and 36.7 (95%CI 27.9, 48.2) respectively per 100,000 persons with diabetes.  Thereafter, the 
rate fell to 46.9 (95%CI 38.0, 57.9), 27.8 (95%CI 21.2, 36.6) and 15.8 (95%CI 11.0, 22.7) respectively 
per 100,000 diabetic population a reduction of 53.4%, 56.9% and 56.9% respectively by 2014-2015. 
The overall reduction over the entire 8 year study for new certifications in persons with diabetes for 
SI and SSI combined, SI and SSI was 43.1%, 43.0% and 49.5% respectively (Figure 1).   
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Discussion 
This analysis of new certifications for SI and SSI in Wales from 2007-2008 to 2014- 2015 provides 
information on the changes that occurred over the eight-year observation period due to any cause 
and specifically DR.  Between 2007 and 2015 the number of new certifications for SI and SSI due to 
DR fell from by 23.8% and 35.7% respectively albeit there was a slight increase in the second year in 
SI and a smaller increase in SII during the fifth year.  In the context of the rising number of persons 
with diabetes (~40%) during the same period of time the proportion of persons with diabetes 
certified as SI and SSI combined, SI or SSI alone almost halved between 2007-2008 and 2014-2015 at 
43.1%, 43.0%, and 49.5% respectively. It is acknowledged that a more prolonged period of 
observation prior to 2007 would have been most helpful in ascertaining the meaningfulness of this 
important trend in lowering of new certification rates for visual impairment in Wales since the 
introduction of a national DR screening service for Wales.     
 
Currently there are a limited number of reports on the number of new certifications for SI and SSI 
due to DR/maculopathy.  For those that do exist it is difficult to compare findings due to different 
methods for certifications and definitions of SI and SSI.  However, recently it was reported that in 
Ireland there were 33 new certifications including both SI and SSI due to DR in 2007 decreasing to 29 
in 2013 which equates to almost halving the risk in persons with diabetes from 45.9 per 100,000 in 
2007 to 26.4 per 100,000 in 2013 (22) which is lower than seen in our population with diabetes in 
Wales.  It is noteworthy that in Ireland prior to the establishment of a National DR screening 
programme DR in 2013 DR screening was performed on a limited basis by local services using 
different models of service provision and the analysis restricted to the 18-69 years of age 
population.  Earlier, in Fife, Scotland the incidence of blindness due to diabetic eye disease during 
1990-1999 was reported to be 64 per 100,000 population/year with diabetes(23). During the 
following decade between 2000 and 2009 the incidence of blindness in Scotland fell by a mean of 
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10.6% per year from 59.7 to 23.9 per 100,000 in the diabetes population (24) which is slightly lower 
than the 30.8 per 100,000 seen in our population in 2009-2010.  The Scottish national screening 
program for DR was implemented  in 2006 midway during our study period.  A comparison of the 
causes of new SSI certifications in England and Wales in working age adults (16-64 years) between 
1999-2000 and 2009-2010 reported a reduction due to DR from 17.7% to 14.4% as the main cause 
and from 17.9% to 16.2% with DR as a main or contributory cause (18).   
 
In our study there are a number of possible explanations as to why the number of new certifications 
of SI and SSI due to DR fell during the eight-year period of observation between 2007-2008 and 
2014-2015.  Screening for DR was introduced in the Wales in 2003 (25, 26), along with the parallel 
availability of new treatments for management of both diabetes and sight-threatening DR and 
maculopathy (27-30). In addition, an increase in the population with diabetes during this period will 
also contribute to this observation due to the greater awareness of diabetes and changes in 
diagnostic criteria. To date, relatively few studies have reported a reduction in the prevalence of 
sight- threatening DR mainly referring to persons with type 1 diabetes (31-33) again suggesting the 
possible benefit of recent changes in the management of diabetes.  In addition a systematic review 
of 28 studies noted that participants involved from 1986 onwards  had a lower proportion of 
proliferative DR and severe vision loss at 2.6% and 3.2% respectively compared to 1985 and before 
at 19.5% and 9.7% respectively (31).  These studies suggest that the reduction in sight-threatening 
DR could possibly be due to improved diabetes and/or ophthalmological care. In our experience in 
Wales the number of people referred by the DESW to the hospital eye services with sight-
threatening DR for ophthalmological review fell from 3.4% in 2007 to 2.0% in 2015 (34).  There has 
also been a decrease in the volume of certifications in England and Wales especially of partially 
sighted people and also there is evidence to suggest an inappropriate severe sight impairment 
certification rate of approximately 20%, due to a variety of reasons (35, 36). Implementation of the 
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National DR screening service will have resulted in a reduction in SSI as a result of the earlier referral 
and treatment of sight-threatening DR by the hospital eye services. In addition providing awareness 
of the presence of DR to Primary Care indicates the need for reviewing diabetes management in 
order to prevent progression of non-sight threatening DR. It would be difficult to say if one or any 
one of these changes were primarily responsible for the observed decrease as it is more likely to be 
a combination of these elements. 
 
Using certifications to study rates of sight impairment is justified on the grounds of coverage and the 
collection of uniform data fields and working definitions of visual impairment both partial sighted 
and blindness. However, there are major limitations which are well described by others (14-16) 
acknowledging the fact that certification is hospital and not population based which requires the 
patient to access hospital based services in order to be seen and certified by a consultant 
ophthalmologist. A substantial proportion of visually impaired persons (approximately 50%) remain 
uncertified and certification is deemed inappropriate in approximately 23% (15,32,34). Patient and 
healthcare professional knowledge and attitude relating to certification for visual impairment can 
also have a negative impact.  Understandably the offer of certification can be distressing for patients 
and they may therefore need time to come to terms with this realisation as well as understanding 
the important benefits certification may bring (17).  Ophthalmologists can be uncertain as to when 
to offer certification, which results in unnecessary delay between the diagnosis of certifiable sight 
loss and the offer of certification with a bias towards SSI, permanent, non-treatable causes, and 
those with t central rather than peripheral vision loss (37, 38).  Unfortunately, blind certification 
does not equate with rates of blindness.  Our analysis provides data on the incidence of new 
certifications for SI and SSI in Wales as a result of DR over an 8-year period since the introduction of 
a nationwide DR screening service (DESW). The findings need to be interpreted acknowledging the 
inherent limitations of the current state of visual impairment certifications where unfortunately 
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blind certification does not equate with blindness rates. Due to these limitations and different 
definitions of sight and severe sight impairment in other countries and settings it would be difficult 
to apply these findings to other settings outside of the UK. 
 
Trends in SI and SSI certifications due to DR are clearly decreasing in Wales as in other regions of the 
UK (18, 22, 24) although the reasons need to be more fully elucidated and confirmed with further 
analysis over the coming years. Studies have also indicated that those persons most at risk of losing 
vision due to DR either do not attend for eye screening and/or are not fully engaged with the 
management of their diabetes (39-43).  In order to ensure the reduced risk for sight loss due to DR in 
Wales continues, more needs to be done to improve attendance rates for eye screening above its 
current and stable level at approximately 80%. Studies are currently underway to explore this very 
important question and to ensure a better uptake into the screening services in order to 
accommodate this vulnerable segment of the population of people with diabetesIncreased access 
to structured diabetes education program is another essential way to help those with diabetes to 
better understand the importance of regular DR screening and the need to achieve and maintain 
good glycaemic, blood pressure and lipid control.   
 
In conclusion, findings from this analysis provides positive and useful epidemiological information to 
assist in the future monitoring of diabetic eye disease in order to provide the basis for assessing the 
benefit or otherwise of changes in the management of diabetes and diabetic 
retinopathy/maculopathy. However, improvements are needed to the certification process to 
enhance its value by providing reliable and meaningful epidemiological data in support of the 
eventual aim of eradicating preventable vision threatening disease in the ever increasing population 
of people with diabetes and the general population alike. This analysis, despite the inherent 
limitations of the current process for the certification of vision impairment, highlights the 
Page 11 of 21
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
12 
 
positive benefits of introducing a community based screening programme for the 
early detection of sight-threatening diabetic retinopathy. 
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Table 1: Number of new certifications for combined (total), SI and SSI due to any cause in the 
population of Wales 2007-2015  
Visual impairment certifications due to any cause in Wales: n (per 
100,000 population) 
Time 
period 
Population Total Sight 
impairment
 
Severe sight 
impairment 
2007-2008 3,025,867 1582 (52.3) 814 (26.9) 681 (22.5) 
2008-2009 3,038,872 1737 (57.2) 914 (30.1) 777 (25.6) 
2009-2010 3,049,971 1544 (50.6) 802 (26.3) 689 (22.6) 
2010-2011 3,098,346 1425 (46.0) 745 (24.0) 649 (20.9) 
2011-2012 3,074,067 1463 (47.6) 703 (22.9) 721 (23.5) 
2012-2013 3,082,400 1362 (44.2) 696 (22.6) 621 (21.1) 
2013-2014 3,092,000 1302 (42.1) 680 (22.0) 580 (18.8) 
2014-2015 3,099,086 1243 (40.1) 631 (20.4) 568 (18.3) 
 
 
 
Table 2: New certifications for SI and SSI due to DR in the population of Wales 2007 - 2015 
Wales Certifications due to DR: n (per 100,000 population) 
Time 
period 
Population Total
1
 Sight 
impairment
 
Sev re sight 
impairment 
2007-2008 3,025,867 108 (3.6) 64 (2.1) 41 (1.4) 
2008-2009 3,038,872 140 (4.6) 89 (2.9) 51 (1.7) 
2009-2010 3,049,971 118 (3.9) 71 (2.3) 45 (1.5) 
2010-2011 3,098,346 103 (3.3) 62 (2.0) 40 (1.3) 
2011-2012 3,074,067 95 (3.1) 55 (1.8) 38 (1.2) 
2012-2013 3,082,400 98 (3.2) 58 (1.9) 38 (1.2) 
2013-2014 3,092,000 95 (3.1) 62 (2.0) 29 (0.9) 
2014-2015 3,099,086 86 (2.8) 51 (1.6) 29 (0.9) 
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Table 3: New certifications for SI and SSI due to DR in those persons with known diabetes in Wales 
between 2007 and 2015: n (per 100,000 population) 
Time 
period 
Total with 
diabetes
 
Total new 
certifications
 
Sight 
impaired 
Severe sight 
impaired  
2007-2008 131,119 108 (82.4) 64 (48.8) 41 (31.3) 
2008-2009 138,988 140 (100.7) 89 (64.5) 51 (36.7) 
2009-2010 146,173 118 (80.7) 71 (48.6) 45 (30.8) 
2010-2011 153,175 103 (67.2) 62 (40.5) 40 (26.1) 
2011-2012 160,533 95 (59.2) 55 (34.3) 38 (23.7) 
2012-2013 167,537 98 (58.5) 58 (34.6) 38 (22.7) 
2013-2014 173,299 95 (54.8) 62 (35.8) 29 (16.7) 
2014-2015 183,348 86 (46.9) 51 (27.8) 29 (15.8) 
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